|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 2334 | Drugs / Medical | 06/20/2003
Kahn Gauthier Swick is investigating possible legal actions against Ethicon Inc. on behalf of women who were harmed by the use of GYNECARE INTERGEL Adhesion Prevention Solution in the course of gynecological or other surgery. GYNECARE INTERGEL is a thick liquid (gel) made of sodium hyaluronate and iron. It is used during gynecological surgery to separate and protect tissues as they heal, preventing adhesions. This product was voluntarily recalled on April 16 due to adverse reaction reports.
Adverse reactions that have been reported include late-onset post-operative pain and repeat surgeries following the onset of pain, non-infectious foreign body reactions, and tissue adherence. In some patients a residual material was observed during the repeat surgery. Post-operative pain could be suggestive of other serious complications, and physicians should be aware of this in managing patients in the post-operative period. GYNECARE has received 103 complaints worldwide of pain, internal scarring and repeat surgeries, the U.S. Food and Drug Administration (FDA) has said. Seventy-two of the reports, including three deaths, are from the United States. The FDA said that the reports alone did not establish any cause and effect for the problems, but merely suggested further inquiry. GYNECARE INTERGEL is intended to be used in open, conservative gynecological surgery as an adjunct to good surgical technique to reduce post-surgical adhesions. Some of the reported adverse events occurred with off-label use in laparoscopy and non-conservative surgical procedures such as hysterectomy. GYNECARE INTERGEL was approved for use in the United States on November 16, 2001. It is made by GYNECARE Worldwide, a division of Ethicon Inc., which is itself owned by Johnson & Johnson. GYNECARE's Customer Hotline is (800) 551-7683. Register your Ethicon Gynecare Intergel ComplaintIf you or someone you know has been affected by this case, you may qualify for a money settlement as the result of your financial/economic or other damages that may be awarded either prior to a lawsuit or after the initiation of a lawsuit either currently in progress or filed just for you, possibly a class action lawsuit. Please simply register your complaint by clicking here for Ethicon Gynecare Intergel, or click the red "submit" button on this page, and a lawyer will review your Ethicon Gynecare Intergel complaint. By submitting your complaint, you are asking lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered - the lawyers work on "contingency" by fronting the costs of your lawsuit based on their belief that they will recover a settlement for you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest Kahn Gauthier Swick is investigating possible legal actions against drug giant Pfizer, Inc., the manufacturer of the prescription drug Neurontin (gabapentin), to recover for harm suffered by patients who have been prescribed Neurontin. The label of widely prescribed antibiotic Ketek will be updated to reflect reports of severe liver problems, including several deaths, associated with its use, the drug's maker and health officials confirmed.
Sanofi-Aventis' Ketek will carry a bold-type warning about reports of liver failure and severe injury, some of them fatal, in patients treated with the drug. A national class action has been filed against prescription drug plan operator Express Scripts, Inc. on behalf of all U.S. citizens who were or are participants in or beneficiaries of any employer-provided prescription benefit plan (1) that required participants or beneficiaries to pay a percentage co-pay for prescription drugs and (2) for which Express Scripts, Inc. or one of its predecessors-in-interest or subsidiaries serves or has served as the plan's provider of prescription drugs at any time from October 1, 1997, through the present. The action is brought under the Employee Retirement Income Security Act (ERISA) and claims that Express Scripts breached its fiduciary duty to plan participants and beneficiaries in several ways. The participants are seeking declaratory and injunctive relief and a court order requiring Express Scripts to make an accounting of and reimburse consumers and benefit plans all monies earned through allegedly unlawful activities.
An administrative proceeding has been filed by the Federal Trade Commission against Boston-area marketers Direct Marketing Concepts, Inc., ITV Direct, Inc., along with business partners Healthy Solutions, LLC, and Health Solutions, Inc., Triad ML Marketing, Inc., and King Media, Inc., on behalf of all persons who purchased the dietary supplements “Supreme Greens with MSM” and “Coral Calcium Daily.” The action alleges that the companies falsely promoted the supplements as a means to treat, cure, and prevent cancer and other diseases, and to cause significant weight loss, in violation of the federal FTC Act. The parties have reached a tentative $2.5 million settlement of a class action filed against respiratory therapy manufacturer Nellcor Puritan Bennett, Inc. (formerly Nasdaq: NELL), subsidiary of Tyco Healthcare/Mallinckrodt, and certain of its officers and directors by stockholders who purchased the company's common stock between September 29, 1995, and April 16, 1996. The actions claim that the defendants violated the California Corporations Code by issuing a series of material misrepresentations to the market over this time period for the purpose of inducing investors to buy the company’s stock. To recover under the settlement, a completed proof of claim postmarked no later than February 18, 2004, must be mailed to the claims administrator. The class has been certified in an action filed against O'Neal, Jones & Feldman Pharmaceuticals, and Carter-Glogau Laboratories on behalf of all persons who received injections of E-Ferol, a vitamin E supplement later to be found toxic. Persons eligible to take part in the action should contact the attorneys for the class for more information. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
